Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating reiterated by stock analysts at Numis Securities Ltd in a research report issued to clients and investors on Wednesday, StockTargetPrices.com reports. They presently have a GBX 252 ($3.36) price target on the stock. Numis Securities Ltd’s price target points to a potential upside of 48.24% from the company’s previous close.
A number of other equities research analysts have also recently commented on the company. Beaufort Securities reiterated a “speculative buy” rating on shares of Horizon Discovery Group PLC in a research note on Friday, May 13th. Panmure Gordon reiterated a “buy” rating and set a GBX 270 ($3.60) target price on shares of Horizon Discovery Group PLC in a research note on Thursday, September 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of GBX 231.50 ($3.08).
Horizon Discovery Group PLC (LON:HZD) remained flat at GBX 170.00 on Wednesday. The stock had a trading volume of 59,222 shares. The company’s market capitalization is GBX 159.95 million. Horizon Discovery Group PLC has a 52 week low of GBX 125.00 and a 52 week high of GBX 188.06. The stock has a 50-day moving average of GBX 159.33 and a 200-day moving average of GBX 159.68.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/horizon-discovery-group-plcs-hzd-buy-rating-reaffirmed-at-numis-securities-ltd.html
Horizon Discovery Group PLC Company Profile
Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com’s FREE daily email newsletter.